Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
All News
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA).
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo.
JAMA has published a current Clinical Guidelines Synopsis on the Management of Crohn Disease (CD) in Adults.
